country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P990084

Copy Link Print Information

Biologically Validated

Veligrotug

Name: Veligrotug
Brand: MedChemExpress
SKU: HY-P990084
Price: 300.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: AVE1642; VRDN-001)

Kundenbewertung

Based on 1 Customer Validation

Veligrotug (AVE1642) is a selective, fully human IGF-1R antagonist antibody with a K_d value of 0.55 nM for hIGF-1R. Veligrotug blocks the phosphorylation of downstream AKT. Veligrotug is applicable to research related to thyroid eye disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.25%
CAS. Nr.: 2728655-31-8
Molecular Weight:147.7 kDa

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Veligrotug Chemical Structure

CAS. Nr.: 2728655-31-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Verified Bioactivity
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

IGF1R/CD221

Alle Akt Isoform-spezifische Produkte anzeigen :

In Vitro

Veligrotug binds to recombinant hIGF-1R ECD protein with high affinity, with a mean K_d value of 0.55 nM^[2].
Veligrotug (30 min) binds with high affinity to HOCF cells endogenously expressing IGF-1R, with a mean EC₅₀ of 2.41 nM and a mean K_d of 1.85 nM^[2].
Veligrotug (0.46-1000 nM; 1 h) does not inhibit insulin-mediated insulin receptor phosphorylation in HepG2 cells even at concentrations as high as 1000 nM^[2].
Veligrotug (0.008-500 nM; 30 min preincubation on ice) almost completely inhibits the binding of IGF-1 to IGF-1R on FreeStyle 293-F cells at concentrations ≥50 nM^[2].
Veligrotug (0.0001-333 nM; 1 h) completely inhibits IGF-1-mediated AKT phosphorylation in primary HOCF cells at concentrations of 10-30 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA Assay^[2]

Cell Line:

HepG2 cells
Concentration:

0.46-1000 nM
Incubation Time:

1 h preincubation at 37°C and 5% CO₂
Result:

Showed no significant antagonism of insulin-mediated IR phosphorylation in HepG2 cells at concentrations up to 1000 nM.

Parmacokinetics

Species	Dose	Route	C_max	T_1/2	V_ss
Cynomolgus Monkey^[2]	2 mg/kg	i.v.	52.2 μg/mL	76.56 h	58.7 mL/kg
Cynomolgus Monkey^[2]	10 mg/kg	i.v.	243 μg/mL	130.08 h	74.2 mL/kg
Cynomolgus Monkey^[2]	50 mg/kg	i.v.	1080 μg/mL	171.6 h	107 mL/kg

In Vivo

Veligrotug (10-50 mg/kg; i.v.; weekly 30-minute infusion; 13 weeks) sustains an approximately 2.5-fold increase in serum IGF-1 concentrations in male and female cynomolgus monkeys throughout the dosing period, while the 2 mg/kg group loses this effect due to anti-drug antibody development in most animals^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Cynomolgus monkeys (male and female, 2.0 to 2.9 years old, 1.6 to 2.2 kg)^[2]
Dosage:

2 mg/kg; 10 mg/kg; 50 mg/kg
Administration:

i.v.; weekly 30-minute infusion; 13 weeks
Result:

Induced an approximately 2.5-fold increase in IGF-1 concentrations for all dose groups following the first dose (Days 0-7).
Sustained elevated IGF-1 serum concentrations throughout the 13-week dosing period for the 10 and 50 mg/kg dose groups.
Maintained elevated IGF-1 concentrations during the recovery period for the 50 mg/kg dose group.
Saw IGF-1 concentrations return to baseline in 5 of 6 animals in the 2 mg/kg group, correlating with anti-drug antibody development.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

3480 [NCBI]

Accession

P08069

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

Anwendung

ELISA, FACS, Functional assay

Verified Bioactivity

Flow cytometric analysis of 1X10⁶ MCF-7 cells labeling Veligrotug (HY-P990084, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Immobilized IGF1R/IGF-I R Protein, Human (HEK293, HY-P72606) can bind Veligrotug. The ED₅₀ for this effect is 3.569 ng/mL.

Chemical Information

CAS. Nr. 2728655-31-8
Appearance Liquid
Molecular Weight 147.7 kDa
Color Colorless to light yellow
SMILES

[Veligrotug]
Synonyms

AVE1642; VRDN-001
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Turbin R, et al. Veligrotug (VRDN-001), a Full Antagonist Monoclonal Antibody to IGF-1 Receptor, in Active Thyroid Eye Disease (TED): THRIVE Phase 3 Efficacy and Safety Topline Results[J]. Investigative Ophthalmology & Visual Science, 2025, 66(8): 4302-4302.

[2]. Kaplan R, et al. Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs. 2025;17(1):2585616. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Biological Activity
Chemical Information
Reinheit & Dokumentation
Verweise

1/16

Human IgG1 kappa
1/16

Flow cytometric analysis of 1X10⁶ MCF-7 cells labeling Veligrotug (HY-P990084, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
1/16

Immobilized IGF1R/IGF-I R Protein, Human (HEK293, HY-P72606) can bind Veligrotug. The ED₅₀ for this effect is 3.569 ng/mL.
1/16

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Veligrotug

Alle Akt Isoform-spezifische Produkte anzeigen